RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsONCY's immune molecule platform therapy pelareorep is "Phase 3 ready" on the speculated resulted from the Bracelet-1 Phase 2 clinical trial in metastatic breast cancer, along with the potential of an accelerated approval on the recently announced findings from the Goblet 1/2 clinical trial in pancreatic cancer.